• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    10/18/24 8:45:00 AM ET
    $BOXL
    $CLDI
    $GRRR
    Other Consumer Services
    Real Estate
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BOXL alert in real time by email

    ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE:CLDI) and Gorilla Technology Group Inc. (NASDAQ:GRRR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 19, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    • Calidi: https://www.redchip.com/assets/access/cldi_access

    • Gorilla Technology: https://www.redchip.com/assets/access/grrr_access

    In an exclusive interview, Stephen Thesing, Chief Business Officer of Calidi, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Calidi is at the forefront of oncolytic virotherapy (OV), a promising multi-billion-dollar area in cancer treatment. Calidi is pioneering the development of both systemic and localized OVs, leveraging engineered viruses to target and destroy cancer cells while arming the immune system for a comprehensive attack on tumors. Calidi's cell-based technologies uniquely protect OVs from immune system elimination, ensuring higher efficacy and opening the tumor microenvironment to treatment. This approach has shown promising efficacy in initial studies, while their breakthrough IV-based technology and direct tumor administration methods differentiate them within the multi-billion-dollar oncology field.

    Jay Chandan, Chairman and CEO of Gorilla Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. With over 22 years of operational excellence and a portfolio of 29 granted patents globally, Gorilla has established itself as a leader in delivering transformative solutions that drive large-scale digital transformation. The company's advanced technologies, including edge AI, big data analytics, IoT security, and virtualization infrastructure, empower clients across critical sectors such as government, public safety, manufacturing, and energy management to create smarter, safer and more efficient environments. Gorilla's strong financial foundation, innovative technology, and strategic market expansion provide a solid basis for long-term value creation as it continues to lead in the global digital transformation landscape. Gorilla has buy ratings and a mean price target of $29.50 from three analysts.

    About Calidi Biotherapeutics

    Calidi Biotherapeutics (NYSE:CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.

    About Gorilla Technology Group Inc.

    Headquartered in London U.K., Gorilla is a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology. We provide a wide range of solutions, including, Smart City, Network, Video, Security Convergence and IoT, across select verticals of Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare and Education, by using AI and Deep Learning Technologies.

    Our expertise lies in revolutionizing urban operations, bolstering security and enhancing resilience. We deliver pioneering products that harness the power of AI in intelligent video surveillance, facial recognition, license plate recognition, edge computing, post-event analytics and advanced cybersecurity technologies. By integrating these AI-driven technologies, we empower Smart Cities to enhance efficiency, safety and cybersecurity measures, ultimately improving the quality of life for residents.

    For more information, please visit our website: https://www.gorilla-technology.com/

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

    Follow RedChip on Twitter: https://twitter.com/RedChip

    Follow RedChip on YouTube: https://www.youtube.com/@redchip

    Follow RedChip on Rumble: https://rumble.com/c/c-3068340

    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-407-644-4256
    [email protected]

    --END--

    SOURCE: RedChip



    View the original press release on accesswire.com

    Get the next $BOXL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • When will the interviews with Calidi Biotherapeutics and Gorilla Technology air?

      The interviews with Calidi Biotherapeutics and Gorilla Technology will air on Bloomberg TV on October 19, 2024, at 7 p.m. Eastern Time.

    • What area of cancer treatment does Calidi Biotherapeutics focus on?

      Calidi Biotherapeutics specializes in oncolytic virotherapy, leveraging engineered viruses to target and destroy cancer cells, while also enhancing immune response to fight tumors.

    • What technologies does Gorilla Technology Group specialize in?

      Gorilla Technology Group is a leader in digital solutions, particularly in edge AI, big data analytics, and IoT security, aimed at transforming operations in government, public safety, and manufacturing.

    • How does Calidi Biotherapeutics' technology differentiate itself in the oncology field?

      Calidi's unique approach involves using stem cell-based platforms that can carry oncolytic viruses, offering a safer and more efficient way to treat cancer.

    • What is the current analyst rating and price target for Gorilla Technology Group?

      Analysts have rated Gorilla Technology with buy ratings and have set a mean price target of $29.50.

    Recent Analyst Ratings for
    $BOXL
    $CLDI
    $GRRR

    CompanyDatePrice TargetRatingAnalyst
    Boxlight Corporation
    $BOXL
    11/14/2024Buy → Neutral
    Alliance Global Partners
    Calidi Biotherapeutics Inc.
    $CLDI
    11/22/2023$11.00Buy
    H.C. Wainwright
    Calidi Biotherapeutics Inc.
    $CLDI
    10/9/2023$9.00Outperform
    Robert W. Baird
    Gorilla Technology Group Inc.
    $GRRR
    7/26/2023$4.80Overweight
    Cantor Fitzgerald
    Boxlight Corporation
    $BOXL
    12/13/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings